Takeda Pact No Cure-All for Cell Genesys

Cell Genesys(CEGE Quote) landed a partner for its experimental prostate cancer vaccine.

The South San Francisco-based biotech outfit announced Monday night that Japanese drug maker Takeda Pharmaceutical has signed on as a global partner for GVAX Prostate, currently in phase III clinical trials.

As a highly visible and vocal Cell Genesys bear, this is where many people out there may expect me to express how wrong I've been about GVAX Prostate. Clearly, this Takeda partnership is a vindication of Cell Genesys' approach to developing an immunotherapy against prostate cancer; and the new deal assures investors that the ongoing phase III GVAX Prostate cancer trials will be positive once we start seeing data next year.

The problem, however, is that I don't really believe any of that. ...